A roundup of the top stories coming out of France’s pharma industry, including Sanofi’s consumer health unit spinout and EUR 40 million investment in antibody bioproduction; the French govenment’s unprecedented…
With the emergence of GLP-1 RA therapies the obesity drug market has taken off and stands to be worth some USD 125.3 billion by 2033. Eli Lilly and Novo Nordisk…
As Donald Trump assembles his new government, speculations about the consequences of his second presidential term abound. For the life sciences industry, the US president-elect’s more business-friendly stances could entail…
A roundup of some of the top stories coming out of Spain’s life sciences sector, including Brookfield’s ongoing interest in Grifols; Rovi’s change of heart about selling its CDMO business;…
Seen by most as life-sciences friendly, the UK Government’s 2024 Autumn Budget not only pledges to increase funding for the country’s ailing National Health Service (NHS), but to dedicate additional…
With the naming of Armida Zuñiga as head of the country’s regulatory body COFEPRIS, new Mexican president Claudia Sheinbaum has concluded the new government’s healthcare appointments and begun advancing her…
An overview of some of the top stories from China’s pharma industry, including the arrest of AstraZeneca China’s top executive; Pfizer’s USD 1 billion China investment; WuXi AppTec’s continuing revenue…
The participation of Emma Walmsley, CEO of GlaxoSmithKline (GSK), in the FT Live Global Pharma and Biotech Summit coincided with the outcome of the American elections and the historic win…
At this year’s FT Live Global Pharma and Biotech Summit, Takeda’s President and CEO Christophe Weber spoke about the increased challenges for healthcare systems. Weber acknowledged that as cost pressures…
A roundup of top stories from UK pharma and healthcare, including the innovative manufacturing fund comprised in the government’s new life-sciences-focused budget; GSK’s autoimmune therapy deal with Chimagen Biosciences; Northern…
Focused on rare and ultra-rare genetic diseases, Ultragenyx identifies itself as the industry’s most productive company working in the field of high un-met need diseases. With no fewer than four…
With lower labour costs than mainland US, but the same regulatory framework and straightforward market access, Puerto Rico has long presented a compelling value proposition for pharmaceutical manufacturing, a sector…
See our Cookie Privacy Policy Here
